Phase 2 N=16 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 6 participants
Phase 2 N=35 Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants
Phase 2 N=40 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Phase 2 N=82 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Patients Removed From Study Treatment Due to Toxicities — 31 participants
Phase 2 N=2 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Primary Systemic Amyloidosis
Primary: Number of Participants With a Confirmed Hematologic Response — 0; 0; 0 participants
Phase 3 N=11 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Light Chain Deposition Disease · Primary Systemic Amyloidosis
Primary: Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR])…
Phase 2 N=13 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL Amyloidosis
Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), and AEs Leading to Treatment Discontinuation — 4; 3; 6; 13…
Phase 3 N=89 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants
Phase 2 N=70 Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
Amyloidosis
Primary: Maximum Tolerated Dose — 2 participants with DLT
Phase 2 N=35 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Primary Systemic Amyloidosis · Light Chain Deposition Disease
Primary: Complete Hematologic Response — 16 participants
Phase 1 N=27 Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Light-Chain Amyloidosis
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 5; 5; 10 Participants
Phase 2 N=22 Daratumumab for the Treatment of Patients With AL Amyloidosis
AL Amyloidosis
Primary: Assess the Number of Patients Who Respond to Treatment — 5; 13; 2; 1 Participants
Phase 2 N=35 Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Amyloidosis
Primary: Number of Participants With Disease Response — 20 Participants
Phase 2 N=43 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Amorphous, Eosinophilic, and Acellular Deposit · Constipation · Diarrhea
Primary: Assess Efficacy by Confirmed Overall Hematologic Response — 77.1 percentage of paticipants
Phase 3 N=416 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Amyloidosis
Primary: Percentage of Participants With Overall Complete Hematologic Response (CHR) — 18.1; 53.3 percentage of participants — p=<0.0001
Phase 2 N=129 The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
AL Amyloidosis
Primary: Number of Participants With Cardiac Response and Non-Response — 26; 30; 40; 33 Participants — p=0.3190
Phase 2 N=25 Safety and Effect of Doxycycline in Patients With Amyloidosis
Amyloidosis
Primary: Amyloid Cardiomyopathy: BNP — 883 pg/mL — p=0.035
Phase 2 N=10 Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One…
Phase 2 N=27 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
AL Amyloidosis
Primary: Assessing Dose-limiting Toxicity to Determine Maximal Tolerated Dosage at 2 Milligram Dose — 0 Participants
N/A N=50 Cardiac Amyloidosis Discovery Trial
Cardiac Amyloidosis
Primary: Rate of Cardiac Amyloidosis Diagnosis — 24 Participants
N/A N=25 A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Leukemia · Amyloidosis
Primary: Hematologic Response Rate — 2; 4; 8; 9 participants
Phase 2 N=93 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Multiple Myeloma · Plasma Cell Myeloma
Primary: Overall Survival — 68 Months
Phase 2 N=33 A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
Amyloidosis
Primary: Within-Participant Coefficient of Variation [wCV] Associated With the Quantification (SUVmax) of Radioactivity Associated With Organ-Level Radiotracer Uptake — 14.58…
Phase 4 N=23 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
Cardiac Amyloidosis
Primary: Mean Left Ventricular Myocardial F-18 Florbetapir SUVmean — 3.2; 1.7; 5.0 ratio
Phase 2 N=32 Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
Primary Systemic Amyloidosis
Primary: Hematologic Response — 6; 3; 11; 5 Participants
N/A N=812 Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…
Phase 2 N=31 Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
AL Amyloidosis
Primary: Partial Hematologic Response (PHR) Rate — 16 Participants
Phase 3 N=128 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 — 45.3; 29.5 percentage of participants
Phase 3 N=31 Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
ATTR-CM · TTR-CM
Primary: Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12 — 0; 16.1; 9.7; 51.6 percentage of participants